Abstract library

5 results for "Zachert".
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#236 Very Long-term Follow-up (> 5 years) of Renal Function of Neuroendocrine Tumor Patients Treated with Five or More Cycles of Peptide Receptor Radionuclide Therapy (PRRNT)
Introduction: Nephrotoxicity is one of the primary concerns in neuroendocrine tumor (NET) patients (pts.) treated with peptide receptor radionuclide therapy (PRRNT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#238 Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe?
Introduction: Nephrotoxicity is one of the primary concerns in PRRNT of metastasized neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#1020 Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center
Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Prof. Richard P Baum
Keywords: PRRT
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team